Helen Tremlett

List of Publications by Year
in descending order

246 papers	11,585 citations	30070 54 h-index	36028 97 g-index
249 all docs	249 docs citations	249 times ranked	10383 citing authors

#	Article	IF	Citations
1	Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity. Neurology, 2014, 83, 1022-1024.	1.1	953
2	The prevalence of MS in the United States. Neurology, 2019, 92, e1029-e1040.	1.1	765
3	Higher 25â€hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Annals of Neurology, 2010, 68, 193-203.	5.3	388
4	The gut microbiome in human neurological disease: A review. Annals of Neurology, 2017, 81, 369-382.	5.3	388
5	Disability progression in multiple sclerosis is slower than previously reported. Neurology, 2006, 66, 172-177.	1.1	303
6	Gut microbiota in early pediatric multiple sclerosis: a caseâˆ'control study. European Journal of Neurology, 2016, 23, 1308-1321.	3.3	260
7	Association Between Use of Interferon Beta and Progression of Disability in Patients With Relapsing-Remitting Multiple Sclerosis. JAMA - Journal of the American Medical Association, 2012, 308, 247-56.	7.4	234
8	New perspectives in the natural history of multiple sclerosis. Neurology, 2010, 74, 2004-2015.	1.1	226
9	Impact of multiple sclerosis relapses on progression diminishes with time. Neurology, 2009, 73, 1616-1623.	1.1	200
10	Relapses in multiple sclerosis are age- and time-dependent. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 1368-1374.	1.9	194
11	The natural history of secondary progressive multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 1039-1043.	1.9	191
12	Natural history of secondary-progressive multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 314-324.	3.0	187
13	The natural history of primary progressive multiple sclerosis. Neurology, 2009, 73, 1996-2002.	1.1	156
14	Health-related quality of life in multiple sclerosis. Neurology, 2016, 86, 1417-1424.	1.1	156
15	Disease-modifying drugs for multiple sclerosis in pregnancy. Neurology, 2012, 79, 1130-1135.	1.1	150
16	Monthly Ambient Sunlight, Infections and Relapse Rates in Multiple Sclerosis. Neuroepidemiology, 2008, 31, 271-279.	2.3	142
17	Gut microbiota composition and relapse risk in pediatric MS: A pilot study. Journal of the Neurological Sciences, 2016, 363, 153-157.	0.6	137
18	Psychiatric comorbidity is associated with disability progression in multiple sclerosis. Neurology, 2018, 90, e1316-e1323.	1.1	136

#	Article	IF	Citations
19	Longitudinal follow-up of "benign" multiple sclerosis at 20 years. Neurology, 2007, 68, 496-500.	1.1	132
20	Relative mortality and survival in multiple sclerosis: findings from British Columbia, Canada. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 61-66.	1.9	129
21	Mental comorbidity and multiple sclerosis: validating administrative data to support population-based surveillance. BMC Neurology, 2013, 13, 16.	1.8	122
22	Rising prevalence of vascular comorbidities in multiple sclerosis: validation of administrative definitions for diabetes, hypertension, and hyperlipidemia. Multiple Sclerosis Journal, 2012, 18, 1310-1319.	3.0	109
23	Management of Multiple Sclerosis During Pregnancy and the Reproductive Years. Obstetrics and Gynecology, 2014, 124, 1157-1168.	2.4	109
24	Age Related Multiple Sclerosis Severity Score: Disability ranked by age. Multiple Sclerosis Journal, 2017, 23, 1938-1946.	3.0	107
25	Differences in the burden of psychiatric comorbidity in MS vs the general population. Neurology, 2015, 85, 1972-1979.	1.1	106
26	Health-care use before a first demyelinating event suggestive of a multiple sclerosis prodrome: a matched cohort study. Lancet Neurology, The, 2017, 16, 445-451.	10.2	105
27	The multiple sclerosis gut microbiota: A systematic review. Multiple Sclerosis and Related Disorders, 2020, 37, 101427.	2.0	102
28	Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop. Multiple Sclerosis Journal, 2018, 24, 590-603.	3.0	101
29	High incidence and increasing prevalence of multiple sclerosis in British Columbia, Canada: findings from over two decades (1991â€"2010). Journal of Neurology, 2015, 262, 2352-2363.	3.6	100
30	Is late-onset multiple sclerosis associated with a worse outcome?. Neurology, 2006, 67, 954-959.	1.1	95
31	The natural history of primary progressive MS in British Columbia, Canada. Neurology, 2005, 65, 1919-1923.	1.1	94
32	Neonatal and delivery outcomes in women with multiple sclerosis. Annals of Neurology, 2011, 70, 41-50.	5.3	94
33	Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator. Lancet Neurology, The, 2015, 14, 497-505.	10.2	91
34	Associations between the gut microbiota and host immune markers in pediatric multiple sclerosis and controls. BMC Neurology, 2016, 16, 182.	1.8	91
35	Sex differences in comorbidity at diagnosis of multiple sclerosis. Neurology, 2016, 86, 1279-1286.	1.1	86
36	Factors associated with onset, relapses or progression in multiple sclerosis: A systematic review. NeuroToxicology, 2017, 61, 189-212.	3.0	83

#	Article	IF	Citations
37	Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS. Neurology, 2010, 74, 1822-1826.	1.1	82
38	Cancer risk in multiple sclerosis: findings from British Columbia, Canada. Brain, 2012, 135, 2973-2979.	7.6	82
39	Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1050-1056.	1.9	80
40	A Fungal World: Could the Gut Mycobiome Be Involved in Neurological Disease?. Frontiers in Microbiology, 2018, 9, 3249.	3.5	80
41	Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis. Neurology, 2016, 86, 1287-1295.	1.1	79
42	Comorbidity increases the risk of relapse in multiple sclerosis. Neurology, 2017, 89, 2455-2461.	1.1	77
43	Risk Factors Associated with the Onset of Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Systematic Review. BioMed Research International, 2015, 2015, 1-11.	1.9	76
44	Infection-related health care utilization among people with and without multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 1506-1516.	3.0	76
45	Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses. Pharmacoepidemiology and Drug Safety, 2008, 17, 565-576.	1.9	73
46	Characterising aggressive multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1192-1198.	1.9	71
47	Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similarities. Journal of Neurology, 2009, 256, 374-381.	3.6	69
48	Validation of an algorithm for identifying MS cases in administrative health claims datasets. Neurology, 2019, 92, e1016-e1028.	1.1	69
49	Comparison of Statistical Approaches for Dealing With Immortal Time Bias in Drug Effectiveness Studies. American Journal of Epidemiology, 2016, 184, 325-335.	3.4	68
50	Effects of physical comorbidities on disability progression in multiple sclerosis. Neurology, 2018, 90, e419-e427.	1.1	67
51	UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model. BMJ Open, 2014, 4, e004073.	1.9	66
52	Five years before multiple sclerosis onset: Phenotyping the prodrome. Multiple Sclerosis Journal, 2019, 25, 1092-1101.	3.0	66
53	Multiple sclerosis and pregnancy. Neurology, 2009, 73, 1820-1822.	1.1	63
54	The Utility of Administrative Data for Surveillance of Comorbidity in Multiple Sclerosis: A Validation Study. Neuroepidemiology, 2013, 40, 85-92.	2.3	62

#	Article	IF	Citations
55	Marginal Structural Cox Models for Estimating the Association Between Î²-Interferon Exposure and Disease Progression in a Multiple Sclerosis Cohort. American Journal of Epidemiology, 2014, 180, 160-171.	3.4	61
56	Altered tryptophan metabolism is associated with pediatric multiple sclerosis risk and course. Annals of Clinical and Translational Neurology, 2018, 5, 1211-1221.	3.7	55
57	Asthma and multiple sclerosis: an inverse association in a case-control general practice population. QJM - Monthly Journal of the Association of Physicians, 2002, 95, 753-756.	0.5	54
58	The Incidence and Prevalence of Multiple Sclerosis in Nova Scotia, Canada. Canadian Journal of Neurological Sciences, 2013, 40, 824-831.	0.5	53
59	Adherence and persistence to drug therapies for multiple sclerosis: A population-based study. Multiple Sclerosis and Related Disorders, 2016, 8, 78-85.	2.0	53
60	Predicting risk of secondary progression in multiple sclerosis: A nomogram. Multiple Sclerosis Journal, 2019, 25, 1102-1112.	3.0	53
61	The multiple sclerosis prodrome. Nature Reviews Neurology, 2021, 17, 515-521.	10.1	52
62	Perinatal outcomes in women with multiple sclerosis exposed to disease-modifying drugs. Multiple Sclerosis Journal, 2012, 18, 460-467.	3.0	51
63	Temporal trends of disability progression in multiple sclerosis: findings from British Columbia, Canada (1975â€"2009). Multiple Sclerosis Journal, 2012, 18, 442-450.	3.0	50
64	The multiple sclerosis prodrome: Emerging evidence, challenges, and opportunities. Multiple Sclerosis Journal, 2021, 27, 6-12.	3.0	50
65	Evaluating the safety of Î²-interferons in MS. Neurology, 2017, 88, 2310-2320.	1.1	45
66	Socioeconomic status and disability progression in multiple sclerosis. Neurology, 2019, 92, e1497-e1506.	1.1	45
67	Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study. Multiple Sclerosis Journal, 2017, 23, 588-596.	3.0	44
68	Sun exposure over the life course and associations with multiple sclerosis. Neurology, 2018, 90, e1191-e1199.	1.1	44
69	Physical activity and disability outcomes in multiple sclerosis: A systematic review (2011â€"2016). Multiple Sclerosis and Related Disorders, 2018, 20, 169-177.	2.0	43
70	Differing trends in the incidence of vascular comorbidity in MS and the general population. Neurology: Clinical Practice, 2016, 6, 120-128.	1.6	42
71	Five-minute Apgar score as a marker for developmental vulnerability at 5â€¦years of age. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2016, 101, F114-F120.	2.8	42
72	Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis. Journal of Neurology, 2004, 251, 1297-1303.	3.6	41

#	ARTICLE	IF	CITATIONS
73	Oligoclonal bands and cerebrospinal fluid markers in multiple sclerosis: associations with disease course and progression. Multiple Sclerosis Journal, 2013, 19, 577-584.	3.0	41
74	Multiple Sclerosis in Older Adults: The Clinical Profile and Impact of Interferon Beta Treatment. BioMed Research International, 2015, 2015, 1-11.	1.9	40
75	Comorbidity is associated with pain-related activity limitations in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2015, 4, 470-476.	2.0	40
76	A new way to estimate neurologic disease prevalence in the United States. Neurology, 2019, 92, 469-480.	1.1	40
77	Aggressive multiple sclerosis (1): Towards a definition of the phenotype. Multiple Sclerosis Journal, 2020, 26, 1031-1044.	3.0	39
78	Fatigue and Comorbidities in Multiple Sclerosis. International Journal of MS Care, 2016, 18, 96-104.	1.0	38
79	Factors associated with delay to medical recognition in two Canadian multiple sclerosis cohorts. Journal of the Neurological Sciences, 2010, 292, 57-62.	0.6	37
80	Long-Term Persistence With the Immunomodulatory Drugs for Multiple Sclerosis: A Retrospective Database Study. Clinical Therapeutics, 2012, 34, 341-350.	2.5	36
81	Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 251-260.	1.9	36
82	The Incidence and Prevalence of Thyroid Disease Do Not Differ in the Multiple Sclerosis and General Populations: A Validation Study Using Administrative Data. Neuroepidemiology, 2012, 39, 135-142.	2.3	35
83	Diagnoses of Depression and Anxiety Versus Current Symptoms and Quality of Life in Multiple Sclerosis. International Journal of MS Care, 2018, 20, 76-84.	1.0	35
84	Prevalence and incidence of ischemic heart disease in multiple sclerosis: A population-based validation study. Multiple Sclerosis and Related Disorders, 2013, 2, 355-361.	2.0	34
85	Beta‐interferon exposure and onset of secondary progressive multiple sclerosis. European Journal of Neurology, 2015, 22, 990-1000.	3.3	34
86	Multiple sclerosis: effect of beta interferon treatment on survival. Brain, 2019, 142, 1324-1333.	7.6	34
87	The gut microbiota in pediatric multiple sclerosis and demyelinating syndromes. Annals of Clinical and Translational Neurology, 2021, 8, 2252-2269.	3.7	34
88	Fatigue, sleep disorders, anaemia and pain in the multiple sclerosis prodrome. Multiple Sclerosis Journal, 2021, 27, 290-302.	3.0	33
89	Common variation near IRF6 is associated with IFN-Î²-induced liver injury in multiple sclerosis. Nature Genetics, 2018, 50, 1081-1085.	21.4	32
90	Coexistence of Multiple Sclerosis and Alzheimer's disease: A review. Multiple Sclerosis and Related Disorders, 2019, 27, 232-238.	2.0	32

#	Article	IF	Citations
91	Multiple sclerosis in men: management considerations. Journal of Neurology, 2016, 263, 1263-1273.	3.6	30
92	Obstetrical epidural and spinal anesthesia in multiple sclerosis. Journal of Neurology, 2013, 260, 2620-2628.	3.6	29
93	Safety of disease-modifying drugs for multiple sclerosis in pregnancy: current challenges and future considerations for effective pharmacovigilance. Expert Review of Neurotherapeutics, 2013, 13, 251-261.	2.8	29
94	A Review of Safety-Related Pregnancy Data Surrounding the Oral Disease-Modifying Drugs for Multiple Sclerosis. CNS Drugs, 2014, 28, 89-94.	5.9	29
95	Assessment of cancer risk with Î²-interferon treatment for multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1096-1102.	1.9	29
96	A populationâ€based study comparing multiple sclerosis clinic users and nonâ€users in British Columbia, Canada. European Journal of Neurology, 2016, 23, 1093-1100.	3.3	29
97	Increased incidence and prevalence of psoriasis in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2017, 13, 81-86.	2.0	28
98	Serum proteomics in multiple sclerosis disease progression. Journal of Proteomics, 2015, 118, 2-11.	2.4	27
99	Adverse health behaviours are associated with depression and anxiety in multiple sclerosis: A prospective multisite study. Multiple Sclerosis Journal, 2016, 22, 685-693.	3.0	27
100	Adherence to disease-modifying therapies for multiple sclerosis and subsequent hospitalizations. Pharmacoepidemiology and Drug Safety, 2017, 26, 702-711.	1.9	27
101	Birth hospitalization in mothers with multiple sclerosis and their newborns. Neurology, 2013, 80, 447-452.	1.1	26
102	Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review. Expert Opinion on Drug Safety, 2020, 19, 1069-1094.	2.4	26
103	A systematic review of morbidities suggestive of the multiple sclerosis prodrome. Expert Review of Neurotherapeutics, 2020, 20, 799-819.	2.8	26
104	Children and adolescents adjustment to parental multiple sclerosis: a systematic review. BMC Neurology, 2014, 14, 107.	1.8	25
105	Multiple cause of death analysis in multiple sclerosis. Neurology, 2020, 94, e820-e829.	1.1	25
106	The psychosocial and cognitive impact of longstanding â€˜benignâ€™ multiple sclerosis. Multiple Sclerosis Journal, 2011, 17, 1375-1383.	3.0	24
107	The incidence and prevalence of fibromyalgia are higher in multiple sclerosis than the general population: A population-based study. Multiple Sclerosis and Related Disorders, 2012, 1, 162-167.	2.0	24
108	Physical comorbidities increase the risk of psychiatric comorbidity in multiple sclerosis. Brain and Behavior, 2016, 6, e00493.	2.2	24

#	Article	IF	Citations
109	Children of chronically ill parents: Relationship between parental multiple sclerosis and childhood developmental health. Multiple Sclerosis Journal, 2016, 22, 1452-1462.	3.0	24
110	Hospital admissions and MS: temporal trends and patient characteristics. American Journal of Managed Care, 2012, 18, 735-42.	1.1	24
111	Elevated aminotransferases during treatment with interferon-beta for multiple sclerosis: actions and outcomes. Multiple Sclerosis Journal, 2004, 10, 298-301.	3.0	23
112	Natural, innate improvements in multiple sclerosis disability. Multiple Sclerosis Journal, 2012, 18, 1412-1421.	3.0	23
113	Retinal nerve fiber layer thickness in benign multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 1275-1281.	3.0	23
114	Gut microbiome and pediatric multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 64-68.	3.0	23
115	Prodrome in relapsing–remitting and primary progressive multiple sclerosis. European Journal of Neurology, 2019, 26, 1032-1036.	3.3	23
116	Traditional risk factors may not explain increased incidence of myocardial infarction in MS. Neurology, 2019, 92, e1624-e1633.	1.1	23
117	From the prodromal stage of multiple sclerosis to disease prevention. Nature Reviews Neurology, 2022, 18, 559-572.	10.1	23
118	Determinants of neurological disease: Synthesis of systematic reviews. NeuroToxicology, 2017, 61, 266-289.	3.0	22
119	Causes that Contribute to the Excess Mortality Risk in Multiple Sclerosis: A Population-Based Study. Neuroepidemiology, 2020, 54, 131-139.	2.3	22
120	Ten years of adverse drug reaction reports for the multiple sclerosis immunomodulatory therapies: a Canadian perspective. Multiple Sclerosis Journal, 2008, 14, 94-105.	3.0	21
121	Aggressive multiple sclerosis (2): Treatment. Multiple Sclerosis Journal, 2020, 26, 1045-1063.	3.0	21
122	Gut microbiome is associated with multiple sclerosis activity in children. Annals of Clinical and Translational Neurology, 2021, 8, 1867-1883.	3.7	21
123	Multiple sclerosis incidence: A systematic review of change over time by geographical region. Multiple Sclerosis and Related Disorders, 2022, 63, 103932.	2.0	21
124	A longitudinal model for disease progression was developed and applied to multiple sclerosis. Journal of Clinical Epidemiology, 2015, 68, 1355-1365.	5.0	20
125	Persistence and adherence to the new oral disease-modifying therapies for multiple sclerosis: A population-based study. Multiple Sclerosis and Related Disorders, 2019, 27, 364-369.	2.0	20
126	Modelling disease progression in relapsing–remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort. Health Technology Assessment, 2016, 20, 1-48.	2.8	20

#	Article	IF	Citations
127	The incidence and prevalence of multiple sclerosis in Nova Scotia, Canada. Canadian Journal of Neurological Sciences, 2013, 40, 824-31.	0.5	20
128	Prescribing for multiple sclerosis patients in general practice: a case-control study. Journal of Clinical Pharmacy and Therapeutics, 2001, 26, 437-444.	1.5	19
129	High-dose frequency beta-interferons increase the risk of liver test abnormalities in multiple sclerosis: a longitudinal study. Multiple Sclerosis Journal, 2011, 17, 361-367.	3.0	19
130	Birth outcomes of pregnancies fathered by men with multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 1260-1264.	3.0	19
131	Does the Season or Month of Birth Influence Disease Progression in Multiple Sclerosis?. Neuroepidemiology, 2006, 26, 195-198.	2.3	18
132	Genetic variation associated with the occurrence and progression of neurological disorders. NeuroToxicology, 2017, 61, 243-264.	3.0	18
133	The multiple sclerosis microbiome?. Annals of Translational Medicine, 2017, 5, 53-53.	1.7	18
134	Comorbidities Are Associated with Altered Health Services Use in Multiple Sclerosis: A Prospective Cohort Study. Neuroepidemiology, 2018, 51, 1-10.	2.3	18
135	Mining healthcare data for markers of the multiple sclerosis prodrome. Multiple Sclerosis and Related Disorders, 2018, 25, 232-240.	2.0	18
136	Age-related decreases in relapses among adults with relapsing-onset multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 1510-1518.	3.0	18
137	Phenome-wide examination of comorbidity burden and multiple sclerosis disease severity. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	17
138	Performance of administrative case definitions for comorbidity in multiple sclerosis in Manitoba and Nova Scotia. Chronic Diseases and Injuries in Canada, 2014, 34, 145-153.	1.3	17
139	Peripartum depression in parents with multiple sclerosis and psychiatric disorders in children. Multiple Sclerosis Journal, 2016, 22, 1830-1840.	3.0	16
140	The effect of smoking on the symptoms and progression of multiple sclerosis: a review. Journal of Inflammation Research, 2010, 3, 115.	3.5	15
141	Characteristics of multiple sclerosis in aboriginals living in British Columbia, Canada. Multiple Sclerosis Journal, 2012, 18, 1239-1243.	3.0	15
142	Impact of parental multiple sclerosis on early childhood development: A retrospective cohort study. Multiple Sclerosis Journal, 2015, 21, 1172-1183.	3.0	15
143	Incidence of Mood or Anxiety Disorders in Children of Parents with Multiple Sclerosis. Paediatric and Perinatal Epidemiology, 2016, 30, 356-366.	1.7	15
144	Metagenomic Analysis of the Pediatric-Onset Multiple Sclerosis Gut Microbiome. Neurology, 2022, 98, .	1.1	15

#	Article	IF	Citations
145	Timing of birth and disease progression in multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 793-798.	3.0	14
146	Disease onset in familial and sporadic primary progressive multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 694-700.	3.0	14
147	Chronic lung disease and multiple sclerosis: Incidence, prevalence, and temporal trends. Multiple Sclerosis and Related Disorders, 2016, 8, 86-92.	2.0	14
148	Disability progression in aggressive multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 456-463.	3.0	14
149	The Gut Microbiota and Pediatric Multiple Sclerosis: Recent Findings. Neurotherapeutics, 2018, 15, 102-108.	4.4	14
150	Accurate classification of secondary progression in multiple sclerosis using a decision tree. Multiple Sclerosis Journal, 2021, 27, 1240-1249.	3.0	14
151	The Multiple Sclerosis Prodrome: Evidence to Action. Frontiers in Neurology, 2021, 12, 761408.	2.4	14
152	Liver test abnormalities in multiple sclerosis: Findings from placebo-treated patients. Neurology, 2006, 67, 1291-1293.	1.1	13
153	Comparison of statistical approaches dealing with time-dependent confounding in drug effectiveness studies. Statistical Methods in Medical Research, 2018, 27, 1709-1722.	1.5	13
154	Suspected autoimmune hepatitis and primary biliary cirrhosis unmasked by interferon-beta in a multiple sclerosis patient. Multiple Sclerosis and Related Disorders, 2013, 2, 57-59.	2.0	12
155	Informing Medication Discontinuation Decisions among Older Adults with Relapsing-Onset Multiple Sclerosis. Drugs and Aging, 2020, 37, 225-235.	2.7	12
156	Investigation of heterogeneity in the association between interferon beta and disability progression in multiple sclerosis: an observational study. European Journal of Neurology, 2014, 21, 835-844.	3.3	11
157	Characteristics of a population-based multiple sclerosis cohort treated with disease-modifying drugs in a universal healthcare setting. Expert Review of Neurotherapeutics, 2021, 21, 131-140.	2.8	11
158	Primary and Nonprimary Fatigue in Multiple Sclerosis. International Journal of MS Care, 2008, 10, 14-20.	1.0	11
159	Disease-Modifying Drugs for Multiple Sclerosis and Association With Survival. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	11
160	Labor induction and augmentation in women with multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 1182-1189.	3.0	9
161	Birth Outcomes in Newborns Fathered by Men with Multiple Sclerosis Exposed to Disease-Modifying Drugs. CNS Drugs, 2014, 28, 475-82.	5.9	9
162	Association between beta-interferon exposure and hospital events in multiple sclerosis. Pharmacoepidemiology and Drug Safety, 2014, 23, 1213-1222.	1.9	9

#	Article	IF	Citations
163	Health-related quality of life in patients with longstanding 'benign multiple sclerosis'. Multiple Sclerosis and Related Disorders, 2015, 4, 31-38.	2.0	9
164	Interrogation of the Multiple Sclerosis Prodrome Using High-Dimensional Health Data. Neuroepidemiology, 2020, 54, 140-147.	2.3	9
165	Medication adherence in multiple sclerosis as a potential model for other chronic diseases: a population-based cohort study. BMJ Open, 2021, 11, e043930.	1.9	9
166	Interferons and multiple sclerosis: is it plausible that Î²-IFN treatment could influence the risk of cancer among MS patients?. Expert Review of Neurotherapeutics, 2009, 9, 1263-1265.	2.8	8
167	Characteristics associated with drug-induced liver injury from interferon beta in multiple sclerosis patients. Expert Opinion on Drug Safety, 2014, 13, 1305-1317.	2.4	8
168	On the application of statistical learning approaches to construct inverse probability weights in marginal structural Cox models: Hedging against weight-model misspecification. Communications in Statistics Part B: Simulation and Computation, 2017, 46, 7668-7697.	1.2	8
169	The use of satellite data to measure ultraviolet-B penetrance and its potential association with age of multiple sclerosis onset. Multiple Sclerosis and Related Disorders, 2018, 21, 30-34.	2.0	8
170	Drug exposure and the risk of multiple sclerosis: A systematic review. Pharmacoepidemiology and Drug Safety, 2018, 27, 133-139.	1.9	8
171	Use of the new oral disease-modifying therapies for multiple sclerosis in British Columbia, Canada: the first five-years. Multiple Sclerosis and Related Disorders, 2018, 25, 57-60.	2.0	8
172	Disparities in management and outcomes of myocardial infarction in multiple sclerosis: A matched cohort study. Multiple Sclerosis Journal, 2020, 26, 1560-1568.	3.0	8
173	Safety of dimethyl fumarate for multiple sclerosis: A systematic review and meta-analysis. Multiple Sclerosis and Related Disorders, 2020, 46, 102566.	2.0	8
174	Performance of administrative case definitions for comorbidity in multiple sclerosis in Manitoba and Nova Scotia. Chronic Diseases and Injuries in Canada, 2014, 34, 145-53.	1.3	8
175	The metabolic potential of the paediatric-onset multiple sclerosis gut microbiome. Multiple Sclerosis and Related Disorders, 2022, 63, 103829.	2.0	8
176	Malignant melanoma in a multiple sclerosis patient with persistent neutralizing antibodies to interferonâ€beta. European Journal of Neurology, 2008, 15, e4.	3.3	7
177	Progressive lipoatrophy after cessation of glatiramer acetate injections: a case report. Multiple Sclerosis Journal, 2009, 15, 521-522.	3.0	7
178	Symptomatic liver injury (hepatotoxicity) associated with administration of complementary and alternative products (Ayurveda-AP-Mag CapsulesÂ®) in a beta-interferon-treated multiple sclerosis patient. European Journal of Neurology, 2011, 18, e78-e79.	3.3	7
179	The potential role of pharmacogenomics in the prevention of serious adverse drug reactions in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2013, 2, 183-192.	2.0	7
180	The systematic search for risk factors in multiple sclerosis. Lancet Neurology, The, 2015, 14, 237-238.	10.2	7

#	Article	IF	Citations
181	Primary and secondary progressive MS have a similar age at onset of progression â€" NO. Multiple Sclerosis Journal, 2017, 23, 640-642.	3.0	7
182	Interferonâ€Î² treatment and the natural history of relapsingâ€remitting multiple sclerosis. Annals of Neurology, 2008, 63, 125-126.	5.3	6
183	A proposed methodology to estimate the cumulative life-time UVB exposure using geographic information systems: An application to multiple sclerosis. Multiple Sclerosis and Related Disorders, 2013, 2, 29-35.	2.0	6
184	Disease-Modifying Therapies and Adherence in Multiple Sclerosis: Comparing Patient Self-Report with Pharmacy Records. Neuroepidemiology, 2017, 48, 124-130.	2.3	6
185	Identifying optic neuritis and transverse myelitis using administrative data. Multiple Sclerosis and Related Disorders, 2018, 25, 258-264.	2.0	6
186	Dealing With Treatment-Confounder Feedback and Sparse Follow-up in Longitudinal Studies: Application of a Marginal Structural Model in a Multiple Sclerosis Cohort. American Journal of Epidemiology, 2021, 190, 908-917.	3.4	6
187	Disease-modifying drugs for multiple sclerosis and subsequent health service use. Multiple Sclerosis Journal, 2022, 28, 583-596.	3.0	6
188	Higher health care use before a clinically isolated syndrome with or without subsequent MS. Multiple Sclerosis and Related Disorders, 2019, 35, 42-49.	2.0	5
189	Animal exposure over the life-course and risk of multiple sclerosis: A case-control study within two cohorts of US women. Multiple Sclerosis and Related Disorders, 2019, 27, 327-332.	2.0	5
190	Adherence to laboratory monitoring among people taking oral drugs for multiple sclerosis: A Canadian population-based study. Multiple Sclerosis Journal, 2021, 27, 239-249.	3.0	5
191	The multiple sclerosis prodrome is just unspecific symptoms in radiologically isolated syndrome patients â€" No. Multiple Sclerosis Journal, 2021, 27, 1824-1826.	3.0	5
192	Nonprescription medicine use in a multiple sclerosis clinic population. British Journal of Clinical Pharmacology, 2000, 50, 55-60.	2.4	4
193	Treatment With Interferon Beta for Multiple Sclerosisâ€"Reply. JAMA - Journal of the American Medical Association, 2012, 308, 1627.	7.4	4
194	Interferon Beta and Long-term Disability in Multiple Sclerosis. JAMA Neurology, 2013, 70, 651.	9.0	4
195	Disease-modifying drugs for multiple sclerosis in pregnancy: A systematic review. Neurology, 2013, 80, 1068-1069.	1.1	4
196	Association between the use of selective serotonin reuptake inhibitors and multiple sclerosis disability progression. Pharmacoepidemiology and Drug Safety, 2016, 25, 1150-1159.	1.9	4
197	Effect of adherence to the first-generation injectable immunomodulatory drugs on disability accumulation in multiple sclerosis: a longitudinal cohort study. BMJ Open, 2017, 7, e018612.	1.9	4
198	Bayesian analysis of pairâ€matched caseâ€control studies subject to outcome misclassification. Statistics in Medicine, 2017, 36, 4196-4213.	1.6	4

#	Article	IF	Citations
199	MRI utilization during the diagnostic and post-diagnostic phases in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 28, 138-144.	2.0	4
200	Pseudotumor cerebri syndrome with different types of hormonal contraceptives in women of childâ€bearing age. European Journal of Neurology, 2020, 27, 2625-2629.	3.3	4
201	Feasibility of Using a Nationally Representative Telephone Survey to Monitor Multiple Sclerosis Prevalence in the United States. Neuroepidemiology, 2020, 54, 123-130.	2.3	4
202	Care consumption of people with multiple sclerosis: A multichannel sequence analysis in a population-based setting in British Columbia, Canada. Multiple Sclerosis Journal, 2022, 28, 309-322.	3.0	4
203	General practitioners' prescribing data for multiple sclerosis patients indicates a link with asthma. British Journal of General Practice, 2000, 50, 323-4.	1.4	4
204	Disease-Modifying Drug Uptake and Health Service Use in the Ageing MS Population. Frontiers in Immunology, 2021, 12, 794075.	4.8	4
205	Effects of seasons on magnetic resonance imaging-measured disease activity in patients with multiple sclerosis. Annals of Neurology, 2001, 50, 422-422.	5.3	3
206	The risks for falls and fractures in multiple sclerosis. Neurology, 2012, 78, 1902-1903.	1.1	3
207	Management of Multiple Sclerosis During Pregnancy and the Reproductive Years. Obstetric Anesthesia Digest, 2015, 35, 186-187.	0.1	3
208	Adjusting for differential misclassification in matched caseâ€control studies utilizing health administrative data. Statistics in Medicine, 2019, 38, 3669-3681.	1.6	3
209	A multiple sclerosis disease progression measure based on cumulative disability. Multiple Sclerosis Journal, 2021, 27, 135245852098863.	3.0	3
210	Liver and thyroid function and autoimmunity during interferon-beta 1b treatment for multiple sclerosis. Neurology, 2002, 58, 1868-1868.	1.1	2
211	Randomized multicenter trial of natalizumab in acute MS relapses: Clinical and MRI effects. Neurology, 2005, 64, 174-175.	1.1	2
212	What went wrong in the natalizumab trials Comment?. Lancet, The, 2006, 367, 1484-1485.	13.7	2
213	Defining the natural history of MS: the need for complete data and rigorous definitions. Multiple Sclerosis Journal, 2008, 14, 1142-1143.	3.0	2
214	Children of chronically ill parents: the silence of research. Child: Care, Health and Development, 2014, 40, 753-754.	1.7	2
215	Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a caseâ€"control study protocol for dimethyl fumarate-induced lymphopenia. BMJ Open, 2017, 7, e016276.	1.9	2
216	Concussion may not cause multiple sclerosis. Annals of Neurology, 2017, 82, 651-652.	5.3	2

#	Article	IF	Citations
217	The reporting of observational studies of drug effectiveness and safety: recommendations to extend existing guidelines. Expert Opinion on Drug Safety, 2021, 20, 1-8.	2.4	2
218	Short-term laboratory and related safety outcomes for the multiple sclerosis oral disease-modifying therapies: an observational study. Expert Opinion on Drug Safety, 2021, 20, 481-487.	2.4	2
219	Coexistence of Multiple Sclerosis and Alzheimer Disease Pathology: A Case Series. Journal of Neurology Research, 2021, 11, 60-67.	0.5	2
220	Stability of the gut microbiota in persons with paediatric-onset multiple sclerosis and related demyelinating diseases. Multiple Sclerosis Journal, 2022, 28, 1819-1824.	3.0	2
221	Contents Vol. 26, 2006. Neuroepidemiology, 2006, 26, 243-244.	2.3	1
222	Increasing Levels of Serum Vitamin D are Associated with Lower Rates of Relapse in Multiple Sclerosis. Journal of Clinical Neuroscience, 2009, 16, 1520.	1.5	1
223	Epidemiology in multiple sclerosis has had its day: there are no more unanswered questions - No. Multiple Sclerosis Journal, 2012, 18, 138-139.	3.0	1
224	THE UK MS RISK-SHARING SCHEME: RESULTS FOR YEARS 4 AND 6. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, e4.24-e4.	1.9	1
225	THE AUTHORS REPLY. American Journal of Epidemiology, 2016, 184, 857-858.	3.4	1
226	Can falling infection rates in one country explain rising incidence of autoimmune and allergic diseases in other countries? Caution when (over) interpreting ecological data from disparate areas. Multiple Sclerosis and Related Disorders, 2018, 21, A3-A5.	2.0	1
227	An â€˜epidemicâ€™ of multiple sclerosis and falling infection rates? Reflecting on comparisons made and the rising multiple sclerosis incidence in Bach's 2002 <i>New England Journal of Medicine</i> figure. European Journal of Neurology, 2018, 25, 196-199.	3.3	1
228	Alemtuzumab and prescription medication use in the MS population. Multiple Sclerosis and Related Disorders, 2020, 42, 102086.	2.0	1
229	High BMI in Youths as a Modifiable Risk Factor for Multiple Sclerosis. Neurology, 2021, 97, 1057-1058.	1.1	1
230	Emergency department use by persons with MS: A population-based descriptive study with a focus on infection-related visits. Multiple Sclerosis Journal, 2022, 28, 1825-1828.	3.0	1
231	Subject Index Vol. 26, 2006. Neuroepidemiology, 2006, 26, 242-242.	2.3	0
232	Author Index Vol. 26, 2006. Neuroepidemiology, 2006, 26, 240-241.	2.3	0
233	Author Index Vol. 31, 2008. Neuroepidemiology, 2008, 31, 285-285.	2.3	0
234	Subject Index Vol. 31, 2008. Neuroepidemiology, 2008, 31, 286-286.	2.3	0

#	Article	IF	Citations
235	Contents Vol. 31, 2008. Neuroepidemiology, 2008, 31, I-IV.	2.3	0
236	The epidemiology of multiple sclerosis. , 0, , 46-55.		0
237	Birth outcomes of pregnancies fathered by men with multiple sclerosis. Journal of the Neurological Sciences, 2013, 333, e381.	0.6	0
238	IMPROVING THE MODEL FOR THE UK MS DISEASE MODIFYING TREATMENT RISK SHARING SCHEME ANALYSIS: A NEW NATURAL HISTORY DATASET. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, e2.97-e2.	1.9	0
239	Author response: Evaluating the safety of Î²-interferons in MS: A series of nested case-control studies. Neurology, 2017, 89, 2022-2023.	1.1	0
240	Contents Vol. 48, 2017. Neuroepidemiology, 2017, 48, I-IV.	2.3	0
241	WED 167â€¦Socioeconomic status and progression of disability in ms. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A21.1-A21.	1.9	0
242	Reply to letter to the editor. Multiple Sclerosis and Related Disorders, 2019, 34, 165.	2.0	0
243	The future of microbiome research in neuroinflammatory disorders. Multiple Sclerosis and Related Disorders, 2020, 40, 102098.	2.0	0
244	Epidemiology of Multiple Sclerosis and Environmental Risk Factors. , 2021, , 137-153.		0
245	Reproductive Issues in Multiple Sclerosis: Parental MS and Child Outcomes (The Research Perspective). , 2017, , 63-72.		0
246	The Microbiome in Multiple Sclerosis. , 2019, , 121-146.		0